Advanced Biomed Inc. enters $600,000 unsecured loan agreement with Jie Wang

Advanced Biomed Inc. (NASDAQ:ADVB) disclosed Monday that it has entered into a loan agreement with Jie Wang, under which the company has borrowed $600,000. The agreement was signed on April 13, 2026, according to a statement in a press release filed with the Securities and Exchange Commission.The loan comes as the company faces cash flow challenges, with negative levered free cash flow of $6.11 million over the last twelve months. An InvestingPro analysis reveals the company is quickly burning through cash, though it maintains a strong current ratio of 8.56 and holds more cash than debt on its balance sheet.

The loan carries an annual interest rate of 10% and is unsecured. The term of the loan is six months from the disbursement date, with an option for both parties to extend it for an additional six months by mutual written agreement. The company’s minimal debt load, with a debt-to-equity ratio of just 0.08, suggests it has room for additional borrowing if needed.

Advanced Biomed is required to repay the full principal amount of $600,000, along with any accrued and unpaid interest, on or before the maturity date. The company retains the right to prepay the loan in whole or in part at any time without penalty. Any partial prepayments will first be applied to accrued interest and then to the outstanding principal.

The agreement is governed by the laws of the State of New York, and any disputes will be resolved in New York courts. The company stated that it intends to use the loan proceeds for operational purposes.

This information is based on a press release statement included in the company’s Form 8-K filing with the SEC.

In other recent news, Advanced Biomed Inc. has announced several significant developments. The company entered into a definitive agreement to acquire Acellent Technologies in an all-stock transaction valued at approximately $1,080,000. This acquisition involves the issuance of 270,000 shares of Advanced Biomed’s common stock. Additionally, Advanced Biomed has declared a 1-for-20 reverse stock split to regain compliance with Nasdaq’s listing requirements, specifically targeting a minimum bid price of $1.00 per share. This move is aimed at ensuring the company’s continued listing on The Nasdaq Capital Market. Furthermore, Advanced Biomed amended its spin-off agreement concerning the sale of its subsidiary, Advanced Biomed (HK) Limited, to Wei Ha Hui. The amendment sets repayment terms for a debt of $6,925,549 owed by the subsidiary to Advanced Biomed Inc. These recent developments highlight the company’s strategic actions in acquisitions, compliance, and financial restructuring.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.